Collectively, our study highlighted the roles of TG2 inhibitors as a potential therapeutic strategy in the prevention of HCC by targeting liver CSCs, which is important in advancing our knowledge about TG2 in liver CSCs. This evidence concerns the gene TGM2 and hepatocellular carcinoma.